ArticleInvestigational new drugs2018

A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers.

Aflah Roohullah et al.PubMed ↗Publisher ↗

No numbers read from the abstract.